<DOC>
	<DOCNO>NCT02928978</DOCNO>
	<brief_summary>This study evaluate ruxolitinib affect premalignant breast cell . One half study participant receive ruxolitinib approximately 15 day , half receive placebo ( sugar pill ) approximately 15 day . Once study participant complete ruxolitinib placebo , participant undergo surgery remove premalignant breast tissue .</brief_summary>
	<brief_title>Ruxolitinib Premalignant Breast Disease</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<criteria>Have breast biopsy show ADH ( atypical ductal hyperplasia ) , ALH ( atypical lobular hyperplasia ) , LCIS ( lobular carcinoma situ ) , DCIS ( ductal carcinoma situ ) require surgical excision . NOTE : Tissue diagnostic biopsy must accessible/available research correlate ( i.e. , tissue block ~10 unstained slide ) . Due nature study , few slide may accept prior permission Protocol Chair insufficient tissue . Women men age 18 older . Adequate hematologic organ function , define follow : Absolute neutrophil count ≥ 1500/mm3 Hemoglobin ≥ 9.0 g/dL Platelet level &gt; 200 x 109/L Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) AST/ALT ≤ 2.5 x institutional ULN Alkaline phosphatase ≤ 5 x institutional ULN Creatinine clearance &gt; 50 mL/min calculate CockroftGault method Willing use concomitant strong CYP3A4 inhibitor could interfere metabolism ruxolitinib ( i.e azole antifungal , clarithromycin , conivaptan , grapefruit juice , mibefradil , nefazodone , protease inhibitor , telithromycin ) . Women child bear potential must negative pregnancy test prior start therapy . The effect ruxolitinib develop human fetus unknown . For reason class C agent potentially teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Ability understand willingness sign write informed consent document . Participants may receive investigational agent within 30 day enrollment . Participants current previous history invasive breast cancer . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , end stage renal disease ( ESRD ) , psychiatric illness/social situation would limit compliance study requirement . Pregnant nursing woman exclude study HIVpositive participant combination antiretroviral therapy ineligible potential pharmacokinetic interaction ruxolitinib . Appropriate study undertake participant receive combination antiretroviral therapy indicate . Prior current treatment JAK inhibitor , indication . Known Hepatitis B C participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Premalignant Breast Disease</keyword>
	<keyword>ALH</keyword>
	<keyword>ADH</keyword>
	<keyword>DCIS</keyword>
	<keyword>LCIS</keyword>
	<keyword>Breast Cancer Prevention</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>